Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age
NCT02184572
Completed
The purpose of this study is to evaluate the immunogenicity and safety of GSK Biologicals' trivalent MMR (Priorix), comparing it to Merck's MMR vaccine (M-M-R II), which is approved for use in the US in healthy children 12 to 15 months of age.
Gender:
ALL
Ages:
Between 12 months and 15 months
Trial Updated:
12/15/2020
Locations: GSK Investigational Site, Ellensburg, Washington
Conditions: Measles; Mumps; Rubella, Measles-Mumps-Rubella Vaccine
Register for Updates
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life
NCT01681992
Completed
The purpose of this study is to evaluate end of shelf-life potency in terms of the immunogenicity and safety of GSK Biologicals' trivalent MMR vaccine, by comparing it to Merck \& Co., Inc.'s MMR vaccine, which is approved for use in the United States (US).
Gender:
ALL
Ages:
Between 12 months and 15 months
Trial Updated:
12/15/2020
Locations: GSK Investigational Site, Ellensburg, Washington
Conditions: Measles, Mumps, Rubella, Measles-Mumps-Rubella Vaccine
Register for Updates
Safety and Efficacy of SA4Ag Vaccine in Adults Having Elective Open Posterior Spinal Fusion Procedures With Multilevel Instrumentation
NCT02388165
Terminated
The purposes of the clinical trial are to determine whether the SA4Ag vaccine can prevent postoperative Staphylococcus aureus infections in patients who are undergoing elective spinal fusion surgery, and to evaluate the safety of SA4Ag in patients who are undergoing elective spinal surgery.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
12/11/2020
Locations: Virginia Mason Medical Center, Seattle, Washington
Conditions: Staphylococcal Vaccine
Register for Updates
Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine in an Elderly Population
NCT02661490
Completed
The purpose of this study is to further develop a formulation and dose regimen of the norovirus GI.1/GII.4 bivalent virus-like particle (VLP) vaccine that is immunogenic and safe in an elderly population aged 60 years and above.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/22/2020
Locations: Group Health Research Institute, Seattle, Washington
Conditions: Norovirus
Register for Updates
Vaccine Therapy in Treating Patients With Breast Cancer
NCT00524277
Completed
RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill tumor cells that express HER2/neu. Biological therapies, such as GM-CSF, may stimulate the immune system in different ways and stop tumor cells from growing. It is not yet known whether vaccine therapy is more effective than GM-CSF in treating breast cancer. PURPOSE: This randomized phase II trial is studying vaccine therapy to see how well it works compared with GM-CSF in treating patients with... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/23/2020
Locations: Madigan Army Medical Center - Tacoma, Tacoma, Washington
Conditions: Breast Cancer
Register for Updates
Vaccine Therapy in Treating Patients Receiving Trastuzumab For HER2-Positive Stage IIIB-IV Breast Cancer
NCT00343109
Completed
This phase II trial is studying how well vaccine therapy works in treating patients receiving trastuzumab for HER2-positive stage IIIB- IV breast cancer. Vaccines made from peptides may help the body build an effective immune response to kill tumor cells
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/07/2020
Locations: Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington
Conditions: HER2-positive Breast Cancer, Male Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Register for Updates
Vaccine Therapy in Treating Patients With Multiple Myeloma Who Have Undergone Stem Cell Transplantation
NCT00002787
Completed
The purpose of this trial is to test the safety and immune response to four immunizations with this vaccine made from a protein produced by the patient's tumor. There is no guarantee or promise that this procedure will be successful
Gender:
ALL
Ages:
All
Trial Updated:
05/02/2019
Locations: Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington
Conditions: Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
Register for Updates
Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection
NCT03146403
Terminated
The main purpose of this clinical study is to see if a maintenance dose of GEN-003 reduces the number of days that subjects have a genital herpes recurrence. The second purpose of the study is to evaluate the safety and tolerability of a maintenance dose of GEN-003.
Gender:
ALL
Ages:
All
Trial Updated:
01/29/2019
Locations: University of Washington, Seattle, Washington
Conditions: Genital Herpes, HSV-2 Infection
Register for Updates
A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the GlaxoSmithKline (GSK) Biologicals' Respiratory Syncytial Virus (RSV) Investigational Vaccine (GSK3003891A) in Healthy Pregnant Women and Infants Born to Vaccinated Mothers
NCT03191383
Withdrawn
The purpose of this study is to assess the safety, reactogenicity and immunogenicity of the investigational GSK RSV vaccine in pregnant women aged 18 to 40 years and infants born to the vaccinated women
Gender:
FEMALE
Ages:
Between 18 years and 40 years
Trial Updated:
10/12/2018
Locations: GSK Investigational Site, Ellensburg, Washington
Conditions: Respiratory Syncytial Virus Infections
Register for Updates
Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of Life
NCT01214837
Completed
The purpose of this study was to assess immunogenicity of a 3-dose versus 4-dose infant vaccination schedule including kinetics of immune response in the early phases of the series.
Gender:
ALL
Ages:
Between 55 days and 89 days
Trial Updated:
09/10/2018
Locations: Rockwood Clinic P S, Spokane, Washington +1 locations
Conditions: Meningococcal Disease, Meningococcal Meningitis
Register for Updates
A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in Adults
NCT01196975
Completed
This study is designed to test the immunogenicity and safety of an investigational influenza vaccine, in adults compared to two other influenza vaccines. This study will also evaluate the lot-to-lot consistency of three vaccine lots.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/22/2018
Locations: GSK Investigational Site, Wenatchee, Washington
Conditions: Influenza
Register for Updates
HerpeVac Trial for Young Women
NCT00057330
Completed
The primary purpose of this study is to see if a herpes vaccine may prevent genital herpes disease in women who are not infected. The study will enroll approximately 7550 healthy women. These women will be randomly assigned to 1 of 2 possible study groups: herpes vaccine (experimental group) or hepatitis A vaccine (control group). Participants will receive their assigned vaccine at 0, 1, and 6 months. Participants will have 9 scheduled study visits and additional unscheduled visits for an evalua... Read More
Gender:
FEMALE
Ages:
Between 18 years and 30 years
Trial Updated:
07/26/2018
Locations: GSK Investigational Site, Seattle, Washington
Conditions: Herpes Simplex Infection
Register for Updates